**Table 2: Summary of finding as per GRADE guidelines @ for use of Swallowed steroids in children with EoE**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Outcome | Absolute risk | Relative effect (RR)95% CI | Number of participants | Quality of evidenceGRADE | Comment |
|  | Estimated risk(Benefit) | Corresponding risk (Benefit) |  |  |  |  |
| Without SS | With SS |  |  |  |  |
| Histological remission | 2/45 | 56/96 | RR =10.32 (3.04, 35.03) | 141 | Low | \*See below |
|  Clinical Remission | NC | NC | NC | NC | Unclear |  |
| Improvement in histology and biopsy | NC | NC | NC | NC | Unclear  |  |

SS : Swallowed Steroids ( Oral viscous budesonide and fluticasone), NC: Not calculable

@: Guyatt G, Oxmanc A, Santesso N et al; GRADE guidelines: 12. Preparing Summary of Findings tables - binary outcomes; *J Clin Epidemiolo 66 (2013) 158e172*

\*The evidence was deemed low in view of the relatively small sample size, heterogeneity of intervention and doses and high risk of bias in some of the included studies.